ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.
Hosted on MSN6h
Study of Oligorecurrent Prostate Cancer Finds Winning Combination
A short course of androgen deprivation therapy (ADT) added to stereotactic body radiotherapy (SBRT) halved the risk of ...